Develops onvansertib, an oral cancer drug candidate used with standard cancer treatments for colorectal, pancreatic, lung and breast cancers, and blood cancers.
10-K for FY2025, filed Feb 24, 2026
Receives royalties tied to sales or use of intellectual property licenses unrelated to onvansertib; payment timing depends on licensees’ sales activity. It also licenses patent rights to healthcare companies, medical laboratories and biotechnology partners.
$593K
10-K for FY2025, filed Feb 24, 2026
$593K ↗
Healthcare companies, medical laboratories and biotechnology partners license patent rights from the company.
10-K for FY2025, filed Feb 24, 2026Royalty and License RevenuesView ↗
No. It lost $45.9M in FY2025.
10-Q for Q3 FY2026, filed Nov 12, 2026
−$8.9MView ↗
8-K, filed Sep 14, 2026
On September 14, 2026, Cardiff Oncology, Inc. (the “Company”) and Nerviano Medical Sciences, S.r.l. (“Nerviano”) entered into a…View ↗
Growing. Revenue grew 65% in 4 years, from $359K in FY2021 to $593K in FY2025, about 13% a year.
Clinical focus
The latest report adds trials in chronic myelomonocytic leukemia and focuses the colorectal cancer program on first-line RAS-mutated disease; the older report described a second-line colorectal cancer program.
10-K for FY2022, filed Mar 2, 2023 10-K for FY2025, filed Feb 24, 2026We are a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies…View ↗
There are several ongoing clinical trials of onvansertib in multiple indications: one trial (CRDF-004) in first-line treatment in patients…View ↗
Phase 1 Investigator-Initiated Clinical Trial in CMMLView ↗
Competes with Boehringer Ingelheim, Cyclacel, BMS, Amgen, Pfizer, and Summit Therapeutics
10-K for FY2025, filed Feb 24, 2026The PLK inhibitor that reached the latest stage of clinical development (Phase 3), is volasertib, a pan-PLK inhibitor developed by…View ↗
Loading...